In the first half of April 2025, the US market for 10-Methoxy Iminostilbene experienced a notable price recovery, reversing the sharp decline observed in March. According to ChemAnalyst, prices are expected to continue rising through the second half of April as market sentiment improves and structural supply adjustments take hold.
In March 10-Methoxy Iminostilbene prices in the US declined significantly, largely due to oversupply conditions, falling freight costs from China, and softened import values. Ample inventories across global supply chains kept availability high, allowing suppliers to lower offers to stimulate limited demand. Weakened industrial output—reflected in a downturn in the US Manufacturing PMI—combined with cooling inflation and cautious procurement behavior, suppressed overall market activity.
Also, adding to the decline was increasing trade tensions and imposition by the US of a 10 percent across-the-board tariff on imports, and then a retaliatory tariff hike to 125 percent by China, which disrupted settled procurement arrangements and led to increased buyer uncertainty. These events also undercut confidence in forward purchasing of 10-Methoxy Iminostilbene, especially from downstream markets like pharmaceuticals and nutraceuticals.
But the 10-Methoxy Iminostilbene price environment changed in early April on the back of a drawdown in overhang inventories and rethinking of import strategies against ongoing tariff pressures. While buyers cleared through available inventory and attempted to realign sourcing channels, market tightness started to surface, particularly for better-quality grades of 10-Methoxy Iminostilbene. Importers, with tariffs and exchange rate volatility leading to increased landed costs, aligned pricing strategies in response, fueling the uptrend in prices.
Although industrial activity remains soft, the initial signs of recovery in procurement activity and the anticipation of tighter import flows have begun to shift market momentum for 10-Methoxy Iminostilbene. With ChemAnalyst projecting continued price increases through the latter half of April, stakeholders are expected to monitor trade developments and inventory movements closely.
While March was marked by aggressive price correction driven by excess supply and weak demand, the first half of April has introduced signs of stabilization and recovery. As global trade uncertainties persist and supply-side adjustments take effect, the US 10-Methoxy Iminostilbene market is likely to remain volatile but biased toward modest price gains in the short term.
